They’ll also have an opportunity to help educate other family members about potential risks. Earlier detection, which increases the chance of a successful outcome, provides a sense of relief from uncertainty. Patients will receive very focused and tailored counseling before and after this test.
The following gene tests are clinically indicated.
Next-Gen Sequencing Multi-Gene with BRCA 1/2 (37 Gene Panel)
APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EGFR, EPCAM, EZH2, FANCC, HRAS, MEN1; MET, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTCH1, PTEN, RAD50, RAD51D, RUNX1, SMAD4, STK11, TP53, VHL (Full sequence with DUP/DEL)
The following limited gene tests are clinically indicated.
Breast, ovarian, uterine cancer genes (22 Gene Panel)
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDK4, EPCAM, EZH2, FANCC, MLH1, MRE11A, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51D, STK11, TP53, VHL (Full sequence with DUP/DEL)
Pancreatic cancer genes (11 Gene Panel)
ATM, BRCA1, BRCA2, EPCAM, EZH2, MLH1, MSH2, MSH6, PALB2, PMS2, TP53
Colon cancer genes (10 Gene Panel)
BRCA1, BRCA2, EPCAM, EZH2, MLH1, MSH2, MSH6, PALB2, PMS2, TP53
Pancreatic cancer genes (11 Gene Panel)
CEBPA, EZH2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, GATA2, NSD1, RUNX1, SBDS, TP532
